Revenue and Profit - Cumulative revenue for the year reached 29.797 billion yuan, a year-on-year increase of 10.70%[3] - Revenue for the reporting period was 8.172 billion yuan, a year-on-year decrease of 11.81%[5] - Total operating revenue for the first three quarters of 2023 reached 29,796,767,468.50 RMB, a 10.7% increase from 26,917,230,015.70 RMB in the same period of 2022[33] - Net profit attributable to shareholders of the listed company was 594.11 million yuan, a year-on-year decrease of 22.51%[3] - Net profit attributable to shareholders of the listed company for the reporting period was 50.56 million yuan, a year-on-year decrease of 66.45%[5] - Net profit attributable to the parent company's shareholders for the first three quarters of 2023 was 594,110,580.95 RMB, a 22.5% decrease from 766,713,701.46 RMB in the same period of 2022[36] - Basic earnings per share for the reporting period were 0.0338 yuan, a year-on-year decrease of 66.43%[5] - Basic earnings per share for the first three quarters of 2023 were 0.3972 RMB, down from 0.5126 RMB in the same period of 2022[36] - Total comprehensive income for the first three quarters of 2023 was 784,369,404.42 RMB, a 16.3% decrease from 937,357,878.93 RMB in the same period of 2022[36] - Minority shareholders' share of net profit for the first three quarters of 2023 was 189,552,201.83 RMB, up from 171,342,195.05 RMB in the same period of 2022[36] Assets and Liabilities - Total assets as of the end of the reporting period were 38.186 billion yuan, an increase of 6.37% compared to the end of the previous year[16] - Equity attributable to shareholders of the listed company was 11.190 billion yuan, an increase of 3.46% compared to the end of the previous year[16] - Total assets as of September 30, 2023, amounted to 38,186,204,975.90, up from 35,898,612,572.08 at the end of 2022[32] - Total liabilities increased to 24,497,885,837.00 RMB as of September 30, 2023, compared to 22,725,525,501.42 RMB at the end of 2022[33] - Long-term borrowings rose to 3,023,356,829.30 RMB, up from 2,250,000,000.00 RMB at the end of 2022[33] - Total equity attributable to the parent company's shareholders as of September 30, 2023, was 11,189,878,367.00 RMB, a 3.5% increase from 10,815,778,221.23 RMB at the end of 2022[33] - Short-term borrowings as of September 30, 2023, were 2,053,924,652.62, more than double the 997,638,872.50 at the end of 2022[32] Cash Flow - Cash flow from operating activities for the period was a net outflow of 334.14 million yuan, mainly due to the settlement of last year's procurement payments[26] - Net cash flow from operating activities in the first three quarters of 2023 was -334.14 million yuan, compared to 185.04 million yuan in the same period of 2022[50] - Net cash flow from investing activities in the first three quarters of 2023 was -227.67 million yuan, compared to 49.89 million yuan in the same period of 2022[50] - Net cash flow from financing activities in the first three quarters of 2023 was -502.77 million yuan, compared to -564.60 million yuan in the same period of 2022[39] - Cash and cash equivalents at the end of the third quarter of 2023 were 2.45 billion yuan, compared to 1.51 billion yuan at the end of the same period in 2022[39] - Cash received from sales of goods and services in the first three quarters of 2023 was 29.82 billion yuan, an increase from 26.43 billion yuan in the same period of 2022[46] - Cash paid for goods and services in the first three quarters of 2023 was 26.81 billion yuan, compared to 23.11 billion yuan in the same period of 2022[50] - Cash received from borrowings in the first three quarters of 2023 was 3.58 billion yuan, an increase from 2.83 billion yuan in the same period of 2022[39] - Cash paid for debt repayment in the first three quarters of 2023 was 3.61 billion yuan, compared to 2.53 billion yuan in the same period of 2022[39] - Cash paid for dividends, profits, and interest in the first three quarters of 2023 was 372.08 million yuan, compared to 351.31 million yuan in the same period of 2022[39] - Cash received from other financing activities in the first three quarters of 2023 was 6.70 million yuan, a significant decrease from 200.00 million yuan in the same period of 2022[39] Legal and Financial Adjustments - The company's subsidiary, Heilongjiang Company, recovered 535,100 yuan and paid 5.1855 million yuan in a lawsuit case[10] - Heilongjiang Company received 3.1098 million yuan in execution payments from a lawsuit against Sanchuan Company[11] - Derivative financial assets increased by 270.46% due to the rise in fair value of held derivative financial assets[27] - Contract assets grew by 94.42% as receivables for warranty deposits increased based on contract fulfillment progress[27] - Other current assets rose by 99.93% due to an increase in deductible input taxes[27] - Long-term receivables decreased by 53.80% as some long-term receivables were recovered[27] - Construction in progress increased by 34.97% due to the expansion of factory relocation projects[27] - Short-term borrowings surged by 105.88% as the company repaid loans due within one year and arranged new borrowings based on operational needs[27] - R&D expenses increased by 49.98% due to higher investment in research and development[27] - Credit impairment losses skyrocketed by 15,964.37% due to a significant increase in bad debt provisions[27] - R&D expenses for the first three quarters of 2023 increased to 73,476,169.58 RMB, a 50% rise from 48,989,827.30 RMB in the same period of 2022[35] Operating Costs - Operating costs for the first three quarters of 2023 were 26,495,902,600.95 RMB, up from 23,475,501,524.21 RMB in the same period of 2022[35]
中国医药(600056) - 2023 Q3 - 季度财报